ANN ARBOR, Mich., June 21, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced the formation of an independent steering committee to support the REVIVE Phase 3 clinical program for ixmyelocel-T, the company’s expanded multi-cellular product. The committee includes renowned leaders in vascular medicine and clinical research who will provide independent oversight and medical and clinical guidance to Aastrom in advancing the REVIVE clinical program for ixmyelocel-T as a potential treatment for critical limb ischemia. Members of the steering committee have extensive experience in late-stage clinical research and have served on several FDA advisory committees.
